🔎 Trials Near Me

Utama › Dermatitis Atopik (Eksim) › Oregon

Kajian klinikal Dermatitis Atopik (Eksim) di Oregon

6 kajian untuk Dermatitis Atopik (Eksim) sedang mencari peserta di lokasi di Oregon.

Bandar di Oregon

Teks kajian rasmi (Bahasa Inggeris)

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

  • Investigational Site, Portland
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT07003425

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

  • Inmagene Site 3, Portland
Mengambil pesertaFasa 2
Umur 18 hingga 74 · Semua jantina · Dikemas kini 12 Ogo 2026 · NCT07037901

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

  • Oregon Health and Science University /ID# 266483, Portland
Mengambil pesertaFasa 3
Umur 2 hingga 11 · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT06461897

A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

  • Leo Pharma Investigational site, Portland
Mengambil pesertaFasa 3
6 Months – 11 Years · Semua jantina · Dikemas kini 7 Jul 2026 · NCT06311682

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

  • Oregon Health and Science University /ID# 263736, Portland
Mengambil pesertaFasa 3
Umur 18 hingga 63 · Semua jantina · Dikemas kini 6 Jul 2026 · NCT06389136

Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

  • Galderma Investigational Site 7073, Gresham
Mengambil pesertaKajian pemerhatian
Umur 12 ke atas · Semua jantina · Dikemas kini 13 Mac 2026 · NCT06988605

Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.